Director Christopher Causey sells 3,000 shares at blended $423.21, reducing stake by 38.1%, amid 37.6% 30-day rally
Christopher Causey, a director at United Therapeutics, executed 3 separate sales totaling 3,000 shares for $1,269,630.00 at prices ranging from $419.63 to $430.00 on 2025-09-02, reducing his holdings from 7,865 to 4,865 shares (a -38.1% reduction). The transaction occurred at a blended average of $423.21, just $19.40 above the current price of $404.81, while the stock trades at -1.3% from its 52-week high of $410.00. The timing is notable given the stock's 37.6% gain over the preceding 30 days and 25.0% gain over 90 days—a period of substantial appreciation—though the company maintains strong fundamentals with a P/E of 14.74 and recent net income of $309,500,000.00 against $798,600,000.00 in quarterly revenue. The magnitude of the position reduction (nearly 2 of every 5 shares sold) suggests a material rebalancing of the director's exposure to UTHR.